Prices delayed by at least 15 minutes | Print


CARL ZEISS MEDITEC AG (AFX)

Sell: €97.8|Buy: €97.9|Change: 1.10 (1.14%)

Open 

€96.5


Previous close 

€96.55


Trade high 

€97.95


Volume 

144,151


Year high 

€126.00


Year low 

€72.60


Dividend yield 

1.08%


Market capitalisation 

€8.73 bn


P/E ratio 

32.87


ISIN 

DE0005313704


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 18/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
CARL ZEISS MEDITEC AG+ 1.14
More...

Company profile

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.